

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
17 July 2025 (17.07.2025)



(10) International Publication Number
WO 2025/151484 A1

(51) International Patent Classification:

A61P 25/28 (2006.01) A61K 39/00 (2006.01)
C07K 16/28 (2006.01)

SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(21) International Application Number:

PCT/US2025/010690

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))
- with sequence listing part of description (Rule 5.2(a))

(22) International Filing Date:

08 January 2025 (08.01.2025)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/618,762 08 January 2024 (08.01.2024) US
63/724,759 25 November 2024 (25.11.2024) US

(71) Applicant: **ZENAS BIOPHARMA, INC.** [US/US]; 852 Winter Street, Suite 250, Waltham, Massachusetts 02451 (US).

(72) Inventors: **MELANSON, Maria**; c/o Zenas BioPharma, Inc., 852 Winter Street, Suite 250, Waltham, Massachusetts 02451 (US). **FISCHER, Tanya**; c/o Zenas BioPharma, Inc., 852 Winter Street, Suite 250, Waltham, Massachusetts 02451 (US). **CIARLONE, Stephanie**; c/o Zenas BioPharma, Inc., 852 Winter Street, Suite 250, Waltham, Massachusetts 02451 (US).

(74) Agent: **KIM, Sang A** et al.; PROSKAUER ROSE LLP, One International Place, Boston, Massachusetts 02110 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UY, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE,

(54) Title: METHODS AND COMPOSITIONS FOR TREATING RELAPSING MULTIPLE SCLEROSIS

(57) Abstract: The present invention provides methods of treating and improving the symptoms of forms of multiple sclerosis using an antibody or antigen-binding fragment thereof that specifically binds human CD19 (e.g., obexelimab).

WO 2025/151484 A1